Objective. To estimate the effect of disease activity, as measured by the European Scleroderma Research Group Activity Index (EScSG-AI), on the risk of subsequent organ damage in a large systemic sclerosis (SSc) cohort.
Introduction
SSc is a chronic CTD with a variable clinical course and a high burden of morbidity and mortality [1, 2] . New therapies for SSc are being studied [35] ; however, many of the treatments yield only modest benefit.
Over the past decade, the assessment of disease activity in SSc has rapidly evolved in view of the need for valid, feasible and reliable outcome measures that can be employed in clinical trials, longitudinal cohorts and treating to target in clinical practice. Significant progress on the development and validation of instruments for the measurement of disease activity in SSc has been achieved by the European Scleroderma Study Group (EScSG). In 2001, the EScSG identified 11 core activity variables, based on the analysis of clinical charts of 290 patients from 19 European SSc centres, and developed a preliminary activity index [6, 7] . The EScSG Activity Index (EScSG-AI) combines single variables into an overall, continuous measure of disease activity. The construct and criterion validity of the EScSG-AI was later verified [811] , but the predictive validity remains unclear.
A previous study using the Canadian Scleroderma Research Group (CSRG) database suggested a link between the EScSG-AI and disease severity in SSc patients [10] . As the study was cross sectional, prior activity could not be associated with current damage. A longitudinal study with serial disease activity and severity measurements, and quantification of activity burden during the observation period, would help to estimate the effect of high levels of disease activity over time on the risk of subsequent severe internal organ involvement in SSc patients. So far, there have been no attempts to quantify this association in detail and report specific estimates of relative risk.
Two variability measures were used in our study to capture variations in disease activity over time in individual patients: the adjusted mean EScSG-AI and the presence of persistently active disease (PAD)/flare. The adjusted mean EScSG-AI across study visits was calculated using a methodology developed previously for another multisystem disease-SLE [12]-and takes into account the length of time spent at a given activity level. PAD/flare captured all cases with the transition from inactive to active disease over time (flare) and sustained high disease activity (PAD).
We hypothesized that a composite EScSG-AI should predict an accrual of organ damage in SSc patients and tested if an initial activity index or some composite of repeated indices over time would have the strongest association with organ damage. The prediction models for specific damage (lung, heart and kidney disease) and subsets (dcSSc and lcSSc) were analysed. Additionally, we studied the relationships between EScSG-AI and currently used endpoints in SSc: the modified Rodnan skin score (mRSS) and patient-and physician-assessed measures of health status.
Methods

Patient selection
SSc patients from the CSRG database who were 518 years of age at the time of diagnosis of SSc with a disease duration from the onset of the first non-Raynaud's symptom of 43 years at the first visit were eligible. The CSRG collects annual data on >1000 SSc patients at 15 Canadian centres, which is stored in a central database. The patients available for this study were those whose baseline visit was between September 2004 (inception date) and July 2015. Clinical information on all patient visits had been recorded prospectively using standardized data collection forms, including a unique identification number; self-reported data (demographics and questionnaires); dates of Raynaud's and first nonRaynaud's symptom onset; selected current and past medications; SSc type (dcSSc vs lcSSc) [13] ; clinical symptoms; complete physical examination with mRSS [14] ; organ parameters; the patient's global assessment of health (on a 010 scale) [15] and changes in health status; physician-assessed measures of disease activity, severity and damage; HAQ Disability Index (HAQ-DI) [16, 17] ; autoantibodies and laboratory parameters. All participating sites obtained ethics approval (centrally and/or locally) and all patients enrolled in the CSRG signed an informed consent. No additional ethical approval or patient consent was required for this study.
SSc patients who had no evidence of end-stage internal organ involvement (definition is given below) initially with available 3 year follow-up data were included to evaluate the predictive value of EScSG-AI. The subanalyses were performed in early dcSSc and lcSSc cohorts.
Assessment of disease activity
Disease activity was determined by measuring the EScSG-AI. As originally established, this weighted 10-point activity index records activity in separate organs or systems [patient-reported worsening in vascular, skin and cardiopulmonary systems during the previous month, mRSS >14; digital necrosis; arthritis; diffusing capacity of carbon monoxide (DLCO) <80% of predicted] as well as laboratory parameters (ESR >30 mm/h; hypocomplementaemia) at each clinic visit. A cut-off 53 served to identify patients with active disease. To capture the variations in disease activity over time we calculated two measures of repeated disease activity: (i) the adjusted mean EScSG-AI was equivalent to the area under the curve of EScSG-AI over time (supplementary data, available at Rheumatology Online) and (ii) the persistently active disease (PAD)/flare (i.e. the sustained high disease activity (EScSG-AI 53 at both baseline and follow-up visits) or an increase in disease activity, defined as a change from inactive at baseline to active at the followup visit. As a comparator, we used the physician's global assessment of disease activity on a visual analogue scale (VAS): How active would you rate the patient's scleroderma for the past week, ranked from 0 to 10, with 10 being the most active disease? Assessment of skin involvement Skin thickness was measured using the mRSS with a rating of 03 at 17 sites [14] . For each eligible patient the following parameters were analysed: severity of skin involvement, as assessed by the mRSS at the first visit; skin thickness progression rate, defined as the mRSS at the first visit divided by disease duration [18] and the adjusted mean mRSS, which was considered to be equivalent to the area under the curve of mRSS over time and calculated similar to the adjusted mean EScSG-AI.
Outcome measurements
In addition to the commonly used assessment of patient status at specific time points (incidence and severity of organ involvement), we quantified deterioration in organ function and health status over time. The severity of the major organ system's involvement was evaluated at each visit on the Medsger severity scale [19] and accrual of a new severity score was considered as disease progression. Mortality was excluded from the analysis due to an insufficient number of patients with SSc-related causes of death in the selected cohort.
The primary outcome of interest was the progression of visceral disease, defined as accrual of a higher severity grade (Á 51) in any of the major internal organ systems (heart, lung, kidney) at the 3 year follow-up visit compared with the initial visit. There were several other outcomes. Measures indicative of disease progression include an increase in severity grade (Á 51) in cardiovascular, pulmonary and renal systems analysed separately; 515% worsening in pulmonary function tests (FVC and/or DLCO) and worsening of the HAQ-DI 50.140 (by the minimal important difference) [2022] . Static measures of disease severity at the follow-up visit were end-stage internal organ involvement, defined as at least one of the following: progressive renal failure with serum creatinine 5300 mg/dl or requiring dialysis; congestive heart failure or/and an arrhythmia attributable to scleroderma requiring treatment; oxygen required due to either SSc-related interstitial lung disease (ILD) or pulmonary hypertension; severity of lung, heart and kidney involvement (analysed separately in each organ system according to the Medsger scale) at the 1 and 3 year follow-up visits; severity of visceral disease at the 1 and 3 year follow-up visits, defined as the sum of severity scores in the major internal organ systems (lung, heart and kidney); physician global assessment of disease severity and damage using a VAS of 010, with 10 being the most severe disease or the most pronounced damage and patient-reported outcomes such as global assessment of health (010), pain (010) and change in health status from much better to much worse (15 with 3 as no change) at the 1 and 3 year follow-up visits (supplementary data, available at Rheumatology Online).
Statistical analysis
Baseline characteristics were calculated by measures of central tendency and proportions. Values were expressed as the mean (S.D.), median with range or percentages, as appropriate. Student's t test or MannWhitney U test was applied for comparison between continuous variables, as well as chi-square or Fisher's exact test for categorical variables. Spearman's or Pearson's tests were used to determine the correlation between disease activity and outcome measures. To explore the effect of initial EScSG-AI and its variability measures on disease outcomes, logistic and linear regression were used: unadjusted and adjusted for sex, age (at both diagnosis and database entry), disease duration and initial severity of organ involvement. To identify specific determinants of disease severity and progression (i.e. prediction model for progression of ILD), we used multivariate logistic and linear analyses, respectively. Univariate analysis was initially performed and variables with P-values <0.20 were selected for stepwise multivariate regression. The sample size recommendations [23, 24] were used to estimate a sample size for varying numbers of predictor variables. The results from the multiple stepwise linear regression technique were presented as non-standardized regression coefficients (B) with standard error and P-values. All data were analysed using SPSS 22.0 software (IBM, Armonk, NY, USA), considering a two-tailed level of P < 0.05 as statistically significant.
Results
A total of 421 patients satisfied the entry criteria. The demographic and disease characteristics of the patients are given in Table 1 .
Relationship between disease activity and severity at baseline (cross-sectional study)
Bivariate analysis revealed that the initial EScSG-AI was associated with the severity of visceral disease (P < 0.0001), in particular, with the severity of lung (P < 0.0001) and kidney involvement (P < 0.002), HAQ-DI (P < 0.0001) and the patient-and physician-assessed measures of health status (Table 2) . A higher visceral severity score at baseline in multivariate linear analysis was closely linked to the EScSG-AI (P < 0.0001), mRSS (P < 0.0001), mRSS 515 (P < 0.005) and dcSSc (P < 0.005). The severity of kidney involvement was associated with the EScSG-AI (P = 0.002), while the severity of ILD was associated with the EScSG-AI (P < 0.0001), mRSS 515 (P < 0.0001) and worsening of skin thickness over the past month (P < 0.001). No associations between heart involvement and disease characteristics were found at baseline.
Relationship between disease activity and disease outcomes over time (prospective study)
Of 197 early SSc patients with no evidence of end-stage disease at the initial visit and 3-year follow-up, one-third (55/163) demonstrated progression of ILD, 17% (26/153) demonstrated progression of heart disease and 0.8% (1/ 137) progression of kidney disease. Deterioration in PFTs was noted in 37% (41/110). The HAQ-DI worsened in 42% (62/149) at the 3-year follow-up visit. During the observation period, most patients (97.1%) did not develop a new internal organ involvement (the percentage of patients with grade 0 on the Medsger severity scale did not change significantly), but the severity of baseline organ involvement increased, mainly due to further deterioration of moderate visceral disease (Fig. 1) .
The adjusted mean EScSG-AI was the best predictor of severity of internal organ involvement at the 3 year followup visit after adjusting for age, disease duration, gender and severity of kidney, lung and heart involvement at the initial visit (Table 3 ). The adjusted mean EScSG-AI was www.rheumatology.oxfordjournals.org also the strongest predictor for decline in FVC and DLCO values and progression of visceral disease at the 3 year follow-up visit (Table 4) .
Subanalyses performed in dcSSc and lcSSc subtypes revealed that the adjusted mean EScSG-AI significantly predicted progression of visceral disease and functional Predictive significance of the EScSG-AI compared with mRSS
During the observation period the adjusted mean EScSG-AI was closely linked to the adjusted mean mRSS in the early SSc cohort overall (r = 0.485, P = 0.0001) and dcSSc patients (r = 0.531, P = 0.001). Compared with the adjusted mean EScSG-AI, the adjusted mean mRSS predicted only an accrual of a higher severity score in the pulmonary system (P = 0.021 and P = 0.029 for SSc overall and dcSSc, respectively) and worsening of the HAQ-DI (P = 0.007 and P = 0.036 for SSc overall and dcSSc, respectively) in the adjusted linear regression analysis. The degrees of these associations were weaker than those for the adjusted mean EScSG-AI (Tables 4 and 5 ). The adjusted mean mRSS was not associated with a decline in PFTs, progression of heart and kidney involvement and development of end-stage disease. Unlike the adjusted mean EScSG-AI, the variations in mRSS captured with the adjusted mean mRSS did not predict the severity of internal organ involvement at the 3 year follow-up visit. The SSc subtype had no effect on lung or heart disease progression over 3 years or HAQ-DI worsening.
Prediction models of disease severity and progression Disease progression was defined as an accrual of a new severity score (Á 51) overall and by specific organ systems. The sample size for these analyses ranged from 110 to 163. Bivariate correlation analysis revealed that ILD progression in the entire cohort was associated with disease activity (baseline EScSG-AI, adjusted mean EScSG-AI, PAD/flare), initial severity of skin involvement (baseline mRSS, skin thickness progression rate) and overlap with RA; heart disease progression was associated with male sex, elevated ESR and possibly the third quartile of the adjusted mean EScSG-AI (Tables 3 and 4 ). The final models by multivariate analysis showed that progression of ILD at the 3 year follow-up in dcSSc can be predicted only by the adjusted mean EScSG-AI [OR 2.622 (95% CI 1.313, 5.234), P = 0.006]. The prediction model of renal disease progression was not established due to an insufficient number of patients.
Severity of internal organ involvement
The severity of heart disease at the 3 year follow-up in the entire cohort was best predicted by older age (P < 0.001), male sex (P < 0.0001), baseline ESR (P < 0.006), longer disease duration (P < 0.008) and South Asian ethnicity (P < 0.0001). Age (P < 0.001) and male sex (P < 0.0001) were the strongest predictors of severity of heart disease in the lcSSc subgroup, while age (P < 0.049) played a significant role in dcSSc patients. The best predictor of renal disease severity at the 3 year follow-up was the initial severity of kidney involvement in the entire cohort and dcSSc (P < 0.0001). There was also a weak association between the severity of renal disease and male sex (P < 0.039).
The severity of ILD was predicted by the adjusted mean EScSG-AI (P < 0.0001), baseline mRSS (P < 0.006), older age (P < 0.023) and initial severity of ILD (P < 0.0001). Both the adjusted mean EScSG-AI and PAD/flare predicted the patient's health status, while the physicianassessed disease severity and damage at 3 years were predictive in the adjusted linear regression analysis (P < 0.0001).
SSc-specific autoantibodies showed predictive significance for severity of organ involvement at the 3 year follow-up visit only in univariate analysis, but dropped out of the model in multivariate analysis: Scl70 positivity was predictive of severe lung involvement, while ACA positivity had a protective effect. None of the SSc-specific autoantibodies was associated with disease progression over 3 years.
Discussion
One of the major challenges facing clinicians managing patients with SSc is to assess a disease state at a particular time and to monitor disease with rapid adjustments in treatment to prevent irreversible organ damage. In the present study we showed that two variability measures of EScSG-AI (the adjusted mean EScSG-AI and PAD/flare) reliably captured all variations in disease activity during the observation period in individual patients with SSc and had the best predictive value for deterioration in health status, disease progression and development of severe internal organ involvement over time. This indicates that EScSG-AI, even measured over a relatively short period of time, plays an important role in predicting patient outcome.
Many prognosis studies have been analysed using simplistic models as though they were cross-sectional studies, even when longitudinal data are available. The incidence of organ-based complications at a specific time point was used as an outcome that gives no insight into an individual's disease course [2527] . We addressed Values in bold are statistically significant. Predictive significance of disease activity was analysed for deterioration in pulmonary function, health status, disease progression and development of end-stage disease at 3 years in early SSc patients.
Á internal organ: accrual of a new severity score in any of the major organ systems (heart, lung or kidney) on the Medsger severity scale; Á heart (lung): accrual of a new severity score in heart (lung) systems on the Medsger severity scale; ÁHAQ-DI, ÁDLCO
and ÁFVC: significant deterioration in these parameters at the 3 year follow-up visit compared with baseline (see Methods section).
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TABLE 5
Odds ratio for disease characteristics and risk of progression over 3 years in early SSc Odds ratio was calculated for demographic and disease characteristics and risk of pulmonary (Á lung, ÁFVC), this shortcoming by studying the accrual of a new severity score on the Medsger scale in major organ systems over time. It is important to note that predictors of disease status at a specific time point (incidence or severity of organ-based complications) may differ from predictors of disease progression. For example, the SSc subtype and disease-specific autoantibodies are believed to be associated with a specific pattern and severity of visceral disease [14, 27, 28] , while disease progression over time depends more on individual response to treatment and whether or not tight disease control is achieved. Indeed, the adjusted mean EScSG-AI was found to be the only predictor of ILD progression in our study, while the severity of ILD over 3 years was predicted by multiple factors (initial severity of ILD, age, extent of skin involvement, Scl-70 positivity, disease activity). The methodological approach with the assessment of both disease severity and progression enabled us to perform a more accurate validation of the EScSG-AI. In terms of cardiac involvement in SSc, there remains conjecture about the relative contributions of atherosclerotic macrovascular disease and myocardial microvascular disease related to SSc [29] . In our proposed model of heart disease progression, the best predictors were those previously found to contribute to coronary heart disease in healthy subjects [30, 31] -older age, male sex and elevated ESR-suggesting that the severity and progression of heart disease in our cohort of SSc patients were more likely due to atherosclerosis. Another possible reason for the failure of the EScSG-AI to predict progression of heart disease might be the lack of reliable and specific characteristics of cardiomyopathy related to SSc. Cardiac rhythm and conduction disturbances and left ventricular ejection fraction are used to rank the severity of heart disease, while the severity of left ventricular diastolic dysfunction might be a more appropriate outcome measure in SSc patients [32] .
The subjective nature of many symptoms and impacts in SSc requires accurate and reliable measurement of these symptoms based on patient self-reports. Patientreported outcomes are acknowledged as complementary to more objective measures and are being incorporated more frequently into clinical trials and clinical practice [33, 34] . We found that the EScSG-AI was strongly associated with patient global assessment of health and physician-assessed measures of disease activity in both dcSSc and lcSSc. The variations in disease activity over time predicted the severity and damage assessed by a physician, as well as the patient global assessment of health at the 1 and 3 year follow-up visits. The changes in the mRSS parallel disease activity, and we compared variations in the mRSS with variations in the EScSG-AI over time in terms of predictive value.
This study has several limitations. First, the patients may not be reflective of those seen in other centres, as the sites have an interest in SSc and other countries have different baseline characteristics for their early SSc patients [35] . The assessment of disease progression could be a limitation. We used an accrual of a new severity score in a major organ system that captured both the cases with newly developed organ damage and progression of existing damage, which might have different underlying pathogenetic processes (and predictors). However, all these cases are indicative of disease progression and can be used for the assessment of predictive validity of the EScSG-AI. Some complications that contribute to the total disease burden were not ascertained, e.g. digital ulceration and gastrointestinal tract involvement for this study, although they are collected in the registry. So far there is no validated global severity score in SSc that lets us measure the total effect of disease. The original global Medsger severity score is unweighted and the items of disparate importance and prognostic value (i.e. digital tip ulceration and heart failure with left ventricular ejection fraction <40%) could result in similar scores. For that reason, out of nine organ systems in the original Medsger severity scale, we focused on the major internal organs that have the greatest impact on mortality.
Another limitation is that lung involvement on the Medsger severity scale is not analysed separately as a fibrosis component and a pulmonary hypertension component, despite the fact that the pathology of these complications is different, as well as their natural history [36] . Certainly some measures overlap between the EScSG-AI and disease severity, which can bias results. Since we used the visceral disease severity score, the only variables that could potentially overlap are worsening of cardiac or/ and pulmonary symptoms (patient-reported) and DLCO in the EScSG-AI and the objective parameters of heart or/ and ILD on the Medsger severity scale. The fact that the EScSG-AI predicted progression of visceral disease in dcSSc, but not lcSSc, suggests that the overlap in PFTs did not significantly affect the results and some other EScSG-AI variables (i.e. mRSS) work as well. The latter was confirmed by the association between the adjusted mean mRSS and deterioration in functional status and ILD. However, the summary effect of the EScSG-AI over time contributed more significantly to progression of visceral involvement and increased risk of subsequent severe visceral disease compared with the mRSS. The mRSS was dichotomized at 414 or >14 to analyse the predictive validity of this measure separately and to compare it later with the composite index to rule out the possibility that a single measure works better or affects the results significantly and the baseline mRSS and a summary effect of the EScSG-AI over time (adjusted mean mRSS) to capture variations in the mRSS over time. The analysis was redone with the mRSS at a cut point of 20, as that is often in the range of inclusion criteria in dcSSc trials and is associated with mortality [37] .
The cross-sectional part of the study demonstrates the associations between the EScSG-AI and measures that are not part of the index (i.e. severity of kidney involvement, HAQ-DI, patient-and physician-assessed measures of health status), along with some measures that could potentially overlap between the EScSG-AI and disease severity and thus bias the results. Indeed, a composite index will be related to variables within the index in a cross-sectional analysis. Multiple statistical testing was done, but the analyses in the regression models were from bivariate or unadjusted analyses to test our hypothesis. However, multiple tests can spuriously yield significant P-values.
Our study had a well-characterized and relatively large cohort. Disease activity burden in our study was measured by the adjusted mean EScSG-AI and PAD/flare. Although several studies have used this approach to capture variations in activity in patients with SLE, this approach is novel in SSc. Other strengths of this study include the unselected SSc population and a study cohort that accurately reflected contemporary disease course and outcome. The latter is of particular importance because patients who have developed SSc in more recent years have been shown to have improved survival and earlier detection of organ disease compared with historical cohorts [27] . As further activity indices in SSc are being developed, knowledge that averaging a repeated measure may perform better than baseline disease activity for predicting damage is important. These data may also aid in study design with respect to the choice of outcomes and in monitoring health status, with rapid adjustment in treatment in clinical practice.
